Effect of E1(64-81) hepatitis G peptide on the in vitro interaction of HIV-1 Fusion Peptide with membrane models

dc.contributor.authorSánchez Martín, Ma. Jesús
dc.contributor.authorBusquets i Viñas, Ma. Antonia
dc.contributor.authorGirona i Brumós, Victòria
dc.contributor.authorHaro, Isabel
dc.contributor.authorAlsina Esteller, Ma. Asunción
dc.contributor.authorPujol Cubells, Montserrat
dc.date.accessioned2020-06-04T15:48:21Z
dc.date.available2020-06-04T15:48:21Z
dc.date.issued2011-09
dc.date.updated2020-06-04T15:48:22Z
dc.description.abstractOne way to gain information about the fusogenic potential of virus-derived synthetic peptides is to examine their interfacial properties and subsequently to study them in monolayers and bilayers. Here, we characterize the physicochemical surface properties of the peptide E1(64-81), whose sequence is AQLVGELGSLYGPLSVSA. This peptide is derived from the E1 structural protein of GBV-C/HGV which was previously shown to inhibit leakage of vesicular contents caused by the HIV-1 fusion peptide (HIV-1 FP). Mixed isotherms of E1(64-81) and HIV-1 FP were obtained and their Brewster angle microscopy (BAM) and atomic force microscopy (AFM) images showed that the peptide mixture forms a different structure that is not present in the pure peptide images. Studies with lipid monolayers (1,2-dimyristoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (DMPG) and 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-(1-glycerol) (DPPG)) show that both peptides interact with all the lipids assayed but the effect that HIV-1 FP has on the monolayers is reduced in the presence of E1(64-81). Moreover, differential scanning calorimetry (DSC) experiments show the capacity of HIV-1 FP to modify the properties of the bilayer structure and the capacity of E1(64-81) to inhibit these modifications. Our results indicate that E1(64-81) interacts with HIV-1 FP to form a new structure, and that this may be the cause of the previously observed inhibition of the activity of HIV-1 FP by E1(64-81).
dc.format.extent11 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec595756
dc.identifier.issn0005-2736
dc.identifier.urihttps://hdl.handle.net/2445/164344
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.bbamem.2011.05.020
dc.relation.ispartofBiochimica et Biophysica Acta-Biomembranes, 2011, vol. 1808, num. 9, p. 2178-2188
dc.relation.urihttps://doi.org/10.1016/j.bbamem.2011.05.020
dc.rights(c) Elsevier B.V., 2011
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationSíntesi de pèptids
dc.subject.classificationHepatitis G
dc.subject.classificationVirus GB C
dc.subject.classificationVIH (Virus)
dc.subject.otherPeptide synthesis
dc.subject.otherHepatitis G
dc.subject.otherGB virus C
dc.subject.otherHIV (Viruses)
dc.titleEffect of E1(64-81) hepatitis G peptide on the in vitro interaction of HIV-1 Fusion Peptide with membrane models
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
595756.pdf
Mida:
2.04 MB
Format:
Adobe Portable Document Format